The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Severe Hypoglycemia and Risks of Vascular Events and Death
Open accessAbstract
BACKGROUND: Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from a large study of intensive glucose lowering to explore the relationship between severe hypoglycemia and adverse clinical outcomes. METHODS: We examined the associations between severe hypoglycemia and the risks of macrovascular or microvascular events and death among 11,140 patients with type 2 diabetes, using Cox proportional-hazards models with adjustment for covariates measured at baseline and after randomization. RESULTS: During a median follow-up period of 5 years, 231 patients (2.1%) had at least one severe hypoglycemic episode; 150 had been assigned to intensive glucose control (2.7% of the 5571 patients in that group), and 81 had been assigned to standard glucose control (1.5% of the 5569 patients in that group). The median times from the onset of severe hypoglycemia to the first major macrovascular event, the first major microvascular event, and death were 1.56 years (interquartile range, 0.84 to 2.41), 0.99 years (interquartile range, 0.40 to 2.17), and 1.05 years (interquartile range, 0.34 to 2.41), respectively. During follow-up, severe hypoglycemia was associated with a significant increase in the adjusted risks of major macrovascular events (hazard ratio, 2.88; 95% confidence interval [CI], 2.01 to 4.12), major microvascular events (hazard ratio, 1.81; 95% CI, 1.19 to 2.74), death from a cardiovascular cause (hazard ratio, 2.68; 95% CI, 1.72 to 4.19), and death from any cause (hazard ratio, 2.69; 95% CI, 1.97 to 3.67) (P<0.001 for all comparisons). Similar associations were apparent for a range of nonvascular outcomes, including respiratory, digestive, and skin conditions (P<0.01 for all comparisons). No relationship was found between repeated episodes of severe hypoglycemia and vascular outcomes or death. CONCLUSIONS: Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes. It is possible that severe hypoglycemia contributes to adverse outcomes, but these analyses indicate that hypoglycemia is just as likely to be a marker of vulnerability to such events. (Funded by Servier and the National Health and Medical Research Council of Australia; ClinicalTrials.gov number, NCT00145925.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the frequency of severe hypoglycemia in these trials was 2 to 3 times higher in the intensive therapy groups”
From Targets for Glycemic Control (2018) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64).”
From Hypoglycemia (2018) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post hoc analysis of clinical trials examining the effects of strict glycemic control on cardiovascular outcomes showed that exposure to severe hypoglycemia was strongly associated with a range of adverse outcomes, including death (2, 3).”
From Effect of Hypoglycemia on QT Interval in Individuals With and Without Type 2 Diabetes: A Randomized Crossover Trial (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“In ADVANCE, where rates of hypoglycemia were low, a similar pattern was found (47).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“a higher mortality was reported in participants with 1 or more episodes of severe hypoglycemia in the ACCORD (30), ADVANCE (31) and VADT trials (25), irrespective of the different treatment arms in which individual participants were allocated.”
From Targets for Glycemic Control (2018) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“An association of level 3 hypoglycemia with mortality was also found in the ADVANCE trial and in clinical practice (77,78).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [77]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“U500 regular insulin (contains 500 units/mL of regular insulin) may improve glycemia in the therapy of persons with DM who have severe insulin resistance (eg, require >200 total units of insulin/day).1102–1105”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1105]
Experimental — accuracy not yet measuredIn the citing paper
“multiple studies have shown a strong relationship between hypoglycemia (severe or not severe) and cardiovascular events and mortality”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [197]
In the citing paper
“All three trials clearly demonstrated that an episode of severe hypoglycemia was associated with an increased risk of subsequent mortality.”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
In the citing paper
“In ADVANCE, where rates of hypoglycemia were low, a similar pattern was found (47).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
In the citing paper
“An association of level 3 hypoglycemia with mortality was also found in the ADVANCE trial (90).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Rovere, M. T. L., Bigger, J. T., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11144-8 · Cited by 3,120
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
Self-citationIntensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Self-citationGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Flagged first, then by citations
Research works printed but not linked: 3
- Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer, 2000.
- Hoekstra JBL, 2009, Diabetologia, 52, 237
- Miller ME, 2009, Diabetologia, 52, 63
Cited by
Sorted by citations
Items 101–200 of 1,002
Garg, R., Hurwitz, S., Turchin, A., & Trivedi, A. (2013) · Diabetes Care · doi:10.2337/dc12-1296 · Cited by 176
Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities
Boucai, L., Southern, W. N., & Zonszein, J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.011 · Cited by 175
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Sonesson, C., Johansson, P. A., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0356-y · Cited by 181
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B. M., Ghosh, S. K., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 182
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Martyn-Nemeth, P. A., Farabi, S. S., Mihailescu, D. V., Nemeth, J., & Quinn, L. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.003 · Cited by 168
on behalf of the DEVOTE Study Group, Zinman, B., Marso, S. P., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Lange, M., Brown‐Frandsen, K., Moses, A. C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4423-z · Cited by 170
Sulfonylureas: A New Look at Old Therapy
Thulé, P. M., & Umpierrez, G. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0473-5 · Cited by 173
Bergenstal, R. M., Ahmann, A., Bailey, T. S., Beck, R. W., Bissen, J., Buckingham, B. A., Deeb, L. C., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700234 · Cited by 173
Fasting Glucose Level and the Risk of Incident Atherosclerotic Cardiovascular Diseases
Park, C., Güallar, E., Linton, J. A., Lee, D., Jang, Y., Son, D. K., Han, E., Baek, S. J., Yun, Y. D., Jee, S. H., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1577 · Cited by 175
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 171
Self-citationHypoglycemia, Diabetes, and Cardiovascular Disease
Snell‐Bergeon, J. K., & Wadwa, R. P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0031 · Cited by 167
Assessing Potential Glycemic Overtreatment in Persons at Hypoglycemic Risk
Tseng, C., Soroka, O., Maney, M., Aron, D. C., & POGACH, L. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12963 · Cited by 161
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study
Seaquist, E. R., Miller, M. E., Bonds, D. E., Feinglos, M. N., Goff, D. C., PETERSON, K. A., Senior, P. A., & for the ACCORD Investigators (2011) · Diabetes Care · doi:10.2337/dc11-0996 · Cited by 161
Severe Hypoglycemia Predicts Mortality in Diabetes
Cryer, P. E. (2012) · Diabetes Care · doi:10.2337/dc12-0749 · Cited by 163
Ceriello, A., Novials, A., Ortega, E., La Sala, L., Pujadas, G., Testa, R., Bonfigli, A. R., Esposito, K., & Giugliano, D. (2012) · Diabetes · doi:10.2337/db12-0224 · Cited by 155
Lazar, H. L., McDonnell, M. E., Chipkin, S. R., Fitzgerald, C. A., Bliss, C. A., & Cabral, H. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31822c5d78 · Cited by 155
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 157
Self-citationDeng, Y., Lu, L., Aponte, L., Angelidi, A. M., Novak, V., Karniadakis, G. E., & Mantzoros, C. S. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00480-x · Cited by 152
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Karter, A. J., Warton, E. M., Lipska, K. J., Ralston, J. D., Moffet, H. H., Jackson, G. G., Huang, E. S., & Miller, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3844 · Cited by 150
Personalized Management of Hyperglycemia in Type 2 Diabetes
Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P., Prato, S. D., Ferrannini, E., Chan, J. C. N., Leiter, L. A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0512 · Cited by 150
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
on behalf of the DEVOTE Study Group, Pieber, T. R., Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pratley, R. E., Woo, V. C., Heller, S. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4422-0 · Cited by 151
Self-citationHypoglycaemic episodes and risk of dementia in diabetes mellitus: 7‐year follow‐up study
Lin, C.-H., & Sheu, W. H. (2012) · Journal of Internal Medicine · doi:10.1111/joim.12000 · Cited by 153
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
Hattori, S. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-382 · Cited by 145
Intensive treatment and severe hypoglycemia among adults with type 2 diabetes
McCoy, R. G., Lipska, K. J., Yao, X., Ross, J. S., Montori, V. M., & Shah, N. D. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2275 · Cited by 143
Feil, D. G., Rajan, M., Soroka, O., Tseng, C., Miller, D. R., & POGACH, L. M. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03726.x · Cited by 145
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19099 · Cited by 141
Global trend of diabetes mortality attributed to vascular complications, 2000–2016
Ling, W., Huang, Y., Huang, Y., Fan, R., Sui, Y., & Zhao, H.-L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01159-5 · Cited by 155
Pathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
Glycemic control in non-diabetic critically ill patients
Farrokhi, F., Smiley, D. D., & Umpierrez, G. E. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.05.004 · Cited by 142
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 141
Self-citationDiabetes Performance Measures: Current Status and Future Directions
O’Connor, P. J., Bodkin, N. L., FRADKIN, J. E., Glasgow, R. E., Greenfield, S., Gregg, E. W., Kerr, E. A., Pawlson, L. G., Selby, J. V., Sutherland, J. E., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0735 · Cited by 139
Wang, J., Alexanian, A., Ying, R., Kizhakekuttu, T. J., Dharmashankar, K., Vasquez-Vivar, J., Gutterman, D. D., & Widlansky, M. E. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.227389 · Cited by 136
Freeman, R. L. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00006-0 · Cited by 137
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 133
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 130
Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related
Akirov, A., Grossman, A., Shochat, T., & Shimon, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2653 · Cited by 127
Davis, S. N., Duckworth, W. C., Emanuele, N., Hayward, R. A., Wiitala, W. L., Thottapurathu, L., Reda, D. J., & Reaven, P. D. (2018) · Diabetes Care · doi:10.2337/dc18-1144 · Cited by 127
Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
Ajjan, R., Slattery, D., & Wright, E. E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0870-x · Cited by 133
Ding, L., Zhang, H., Dai, C., Zhang, A., Yu, F., Mi, L., Qi, Y., & Tang, M. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02172-8 · Cited by 128
Fuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0977-z · Cited by 125
Hypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, M., & Gerich, J. E. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050948 · Cited by 127
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Hanefeld, M., Frier, B. M., & Pistrosch, F. (2016) · Diabetes Care · doi:10.2337/dcs15-3014 · Cited by 124
Lee, A. K., Lee, C. J., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2017) · Diabetes Care · doi:10.2337/dc17-0819 · Cited by 119
Insulin Therapy for the Management of Hyperglycemia in Hospitalized Patients
McDonnell, M. E., & Umpierrez, G. E. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.01.001 · Cited by 125
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Alam, F., Islam, M. A., Mohamed, M., Ahmad, I., Kamal, M. A., Donnelly, R., IDRIS, I. R., & Gan, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41854-2 · Cited by 117
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 113
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Wu, N., Bredin, S. S. D., Guan, Y., Dickinson, K., Kim, D. D., Chua, Z., Kaufman, K., & Warburton, D. E. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020253 · Cited by 110
Diabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 109
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Zinman, B., Marso, S. P., Christiansen, E., Calanna, S., Rasmussen, S., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dc17-2677 · Cited by 109
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
Yale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Personalized medicine: risk prediction, targeted therapies and mobile health technology
Hayes, D. F., Markus, H. S., Leslie, R. D., & Topol, E. J. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-37 · Cited by 105
Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain
Fournier, J., Azoulay, L., Yin, H., Montastruc, J., & Suissa, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6512 · Cited by 108
Tsujimoto, T., Yamamoto‐Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M., & Noda, M. (2013) · Diabetes Care · doi:10.2337/dc13-0701 · Cited by 103
Morales, J., & Schneider, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.004 · Cited by 106
Rys, P., Wojciechowski, P., Rogoz-Sitek, A., Niesyczyński, G., Lis, J., Syta, A., & Malecki, M. T. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0698-4 · Cited by 101
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100
Douros, A., Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc17-0595 · Cited by 102
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Valencia, I., Peiró, C., Lorenzo, Ó., Sánchez‐Ferrer, C. F., Eckel, J., & Romacho, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01161 · Cited by 100
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
The diabetic brain and cognition
Riederer, P., Korczyn, A. D., Ali, S. S., Bajenaru, O. A., Choi, M. S., Chopp, M., Dobrota, V. Đ., Grünblatt, E., Jellinger, K. A., Kamal, M. A., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1763-2 · Cited by 98
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 96
Proinflammatory effects of hypoglycemia in humans with or without diabetes
Ratter, J. M., Rooijackers, H. M. M., Tack, C. J., Hijmans, A. G. M., Netea, M. G., de Galan, B. E., & Stienstra, R. (2017) · Diabetes · doi:10.2337/db16-1091 · Cited by 94
Zhao, Y., Campbell, C. R., Fonseca, V. A., & Shi, L. (2012) · Diabetes Care · doi:10.2337/dc11-2048 · Cited by 95
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 95
Technology in the management of type 2 diabetes: Present status and future prospects
DALY, A. B., & Hovorka, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14418 · Cited by 100
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Dütting, E. D., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 94
Coming full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 91
Management of diabetes in older adults
Sesti, G., Incalzi, R. A., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 96
Eriksson, J. W., Bodegård, J., Nathanson, D., Thuresson, M., Nyström, T., & Norhammar, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.055 · Cited by 90
Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans
Iqbal, A., Prince, L. R., Novodvorský, P., Bernjak, A., Thomas, M. R., Birch, L., Lambert, D., Kay, L. J., Wright, F., Macdonald, I. A., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01168 · Cited by 90
Self-citationMonnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 88
Bedenis, R., Price, A. H., Robertson, C. M., Morling, J. R., Frier, B. M., Strachan, M. W. J., & Price, J. F. (2014) · Diabetes Care · doi:10.2337/dc14-0908 · Cited by 87
Matthaei, S., Catrinoiu, D., Celiñski, A., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Iqbal, N., & Hansen, L. (2015) · Diabetes Care · doi:10.2337/dc15-0811 · Cited by 86
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 88
Leifke, E., Naik, H., Wu, J., Viswanathan, P., DeManno, D. A., Kipnes, M. S., & Vakilynejad, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.43 · Cited by 86
Current management of diabetes mellitus and future directions in care
Chatterjee, S., & Davies, M. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133200 · Cited by 87
Göke, B., Gallwitz, B., Eriksson, J. G., Hellqvist, Å., & Gause‐Nilsson, I. A. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12119 · Cited by 85
Rosenstock, J., Wilson, C., & Fleck, P. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12102 · Cited by 85
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 88
Forst, T. M., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 86
Shao, H., Fonseca, V. A., Stoecker, C., Liu, S., & Shi, L. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0662-1 · Cited by 84
Yun, J., Park, Y., Han, K., Cha, S., Ahn, Y., & Ko, S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0909-y · Cited by 84
Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
Tsujimoto, T., Sugiyama, T., Shapiro, M. F., Noda, M., & Kajio, H. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09259 · Cited by 83
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 81
Update on diabetes in the elderly and in nursing home residents
Migdal, A., Yarandi, S. S., Smiley, D., & Umpierrez, G. E. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.02.010 · Cited by 81
Lin, C., Yang, C., Li, C.-I., Liu, C.-S., Chen, C., Lin, W., Hwang, K.-L., Yang, S.-Y., & Li, T. (2014) · BMC Medicine · doi:10.1186/s12916-014-0165-7 · Cited by 80
Luo, J., Cao, S., Chen, X., Liu, S., Tan, H. S., Wu, W., & Li, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.041 · Cited by 79
Zhang, Z., Chen, X., Lu, P., Zhang, J., Xu, Y., He, W., Li, M., Zhang, S., Jia, J., Shao, S., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0512-z · Cited by 80
Management of Diabetes in the Elderly
Bansal, N., Dhaliwal, R., & Weinstock, R. S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.008 · Cited by 82
Metadata
- Authors
- Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., Grobbee, D. E., Kengne, A. P., Marre, M., & Heller, S.
- Affiliations
- The University of Sydney (AU)
- University Medical Center Utrecht (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- National Health Service (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1410-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2097995302
- Semantic Scholar
- b73e51368b0f6c3d0c425e6670188db927bc8b09
- Cited by
- 1,471
- References
- 31
- Citations by year
- 2026: 33 · 2025: 49 · 2024: 64 · 2023: 60 · 2022: 66 · 2021: 103 · 2020: 119 · 2019: 99 · 2018: 113 · 2017: 103 · 2016: 107 · 2015: 147 · 2014: 106 · 2013: 98 · 2012: 103
- FWCI
- 71.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- severe hypoglycemia, type 2 diabetes, tight glycemic control, macrovascular events, cardiovascular mortality, all-cause mortality, adverse clinical outcomes, diabetes complications, UKPDS
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Gliclazide, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Vascular Diseases, Proportional Hazards Models, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
